Jessica Couvillion Seidman

Jessica Couvillion Seidman

Auto-generated profile, based on publicly available information

Jessica Couvillion Seidman

Sabin Vaccine Institute, Washington, DC, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 July 2024 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
FQFarah Qamar
Farah Qamar
SQSonia Qureshi
Sonia Qureshi
ZHZoya Haq
Zoya Haq
TYTahir Yousafzai
Tahir Yousafzai
IQIbtisam Qazi
Ibtisam Qazi
JSJessica C. Seidman
Jessica C. Seidman
Typhoid remains a persistent contributor to childhood morbidity in communities lacking sanitation infrastructure. Typhoid conjugate vaccine (TCV) is effective in reducing disease risk in vaccinees; however, the duration of protection is unknown. This study measured the longevity of immune response to TCV in children aged under 10 years in Hyderabad, Pakistan, where an outbreak of extensively drug-resistant typhoid has been ongoing. A subset of children who received the TCV as part of the outbreak response were enrolled purposively from March 2018 to February 2019. The participants were followed up until January 2023. Blood samples were taken at baseline, 4-6 weeks, 6 months, and annually 1-4 years after vaccination to measure anti-Vi immunoglobulin (Ig) G levels using enzyme-linked immunosorbent assay. Active phone-based surveillance was performed to identify breakthrough infections. Blood culture was offered to any child with a history of fever ≥3 days within the last 7 days. A total of 81 children received a second dose of TCV in November 2019 during a catch-up campaign organized by the Sindh government. Nearly all participants seroconverted (802 of 837; 95.8%) at 4-6 weeks after vaccination. A total of 4 years after vaccination, 438 of 579 (75.6%) participants remained above the seroconversion threshold. The geometric mean titer (U/mL) of anti-Vi IgG at 4-6 weeks was 832.6 (95% confidence interval [CI]: 768.0-902.6); at 4 years after vaccination, the geometric mean titers in children aged 6 months to 2 years (12.6, [95% CI: 9.8-16.3]) and >2-5 years (40.1, [95% CI: 34.4-46.6]) were lower than in children aged >5-10 years (71.1, [95% CI: 59.5-85.0]). During 4 years of follow-up, nine children had culture-confirmed Salmonella Typhi infection; these infections occurred after a median duration of 3.4 years. All enteric fever cases seroconverted at 4-6 weeks after vaccination and seven (70.0%) remained seroconverted 4 years after vaccination. We observed 95.8% seroconversion after a single dose of TCV. There was a decay in anti-Vi IgG titers, and, at 4 years, approximately 75.6% remained seroconverted. There was a faster decay in children aged ≤2 years. Breakthrough infections were documented after a median 3.4 years after vaccination.

25 March 2024 in Vaccine
Verified
Journal Article
Open access
CWChristopher Weyant
Christopher Weyant
YHYogesh Hooda
Yogesh Hooda
SMSira Jam Munira
Sira Jam Munira
NLNathan C. Lo
Nathan C. Lo
TRTheresa Ryckman
Theresa Ryckman
JAJason R. Andrews
Jason R. Andrews
Typhoid fever causes substantial morbidity and mortality in Bangladesh. The government of Bangladesh plans to introduce typhoid conjugate vaccines (TCV) in its expanded program on immunization (EPI) schedule. However, the optimal introduction strategy in addition to the costs and benefits of such a program are unclear. We extended an existing mathematical model of typhoid transmission to integrate cost data, clinical incidence data, and recently conducted serosurveys in urban, semi-urban, and rural areas. In our primary analysis, we evaluated the status quo (i.e., no vaccination) and eight vaccine introduction strategies including routine and 1-time campaign strategies, which differed by age groups targeted and geographic focus. Model outcomes included clinical incidence, seroincidence, deaths, costs, disability-adjusted life years (DALYs), and incremental cost-effectiveness ratios (ICERs) for each strategy. We adopted a societal perspective, 10-year model time horizon, and 3 % annual discount rate. We performed probabilistic, one-way, and scenario sensitivity analyses including adopting a healthcare perspective and alternate model time horizons. We projected that all TCV strategies would be cost saving compared to the status quo. The preferred strategy was a nationwide introduction of TCV at 9-12 months of age with a single catch-up campaign for children ages 1-15, which was cost saving compared to all other strategies and the status quo. In the 10 years following implementation, we projected this strategy would avert 3.77 million cases (95 % CrI: 2.60 - 5.18), 11.31 thousand deaths (95 % CrI: 3.77 - 23.60), and save $172.35 million (95 % CrI: -14.29 - 460.59) compared to the status quo. Our findings were broadly robust to changes in parameter values and willingness-to-pay thresholds. We projected that nationwide TCV introduction with a catch-up campaign would substantially reduce typhoid incidence and very likely be cost saving in Bangladesh.

2 October 2017 in International Journal of School & Educational Psychology
Verified
Journal Article
Closed access
LPLaura L. Pendergast
Laura L. Pendergast
PJPaul Jones
Paul Jones
RSRebecca Scharf
Rebecca Scharf
MRMuneera Rasheed
Muneera Rasheed
BSBarbara A. Schaefer
Barbara A. Schaefer
TIThe MAL-ED Network Investigators
The MAL-ED Network Investigators
Characteristics of temperament have been shown to predict aspects of personality and psychopathology. Approach temperament (i.e., sensitivity, reactivity, and behavioral disposition toward reward stimuli) may be a particularly salient predictor of developmental outcomes (e.g., Nigg, 2006; Shiner & Caspi, 2003). However, there is little research on approach temperament among children from low- and middle-income nations. This study examined the validity of an adapted version of the Infant Temperament Scale across eight international sites with a focus on approach temperament. Our sample included 1,933 infants from eight study sites in low- and middle-income nations: Bangladesh, Brazil, India, Nepal, Peru, Pakistan, South Africa, and Tanzania. The Infant Temperament Scale was translated and administered as a structured interview to caregivers at each site. Exploratory and confirmatory factor analyses were used to examine the factor structure of the scale, and multiple indicator multiple cause (MIMIC) modeling was used to examine invariance of scores across sites. The findings supported the validity of an approach temperament factor. Although the findings did not support the cross-cultural use of the entire Infant Temperament Scale among individuals from low- and middle-income nations in our sample, the supported approach temperament factor is a theoretically important subconstruct. Moreover, the inability to measure other aspects of temperament across cultures may have important implications for researchers interested in the nature of temperament. Implications and future directions are discussed.

1 April 2025 in The Lancet Regional Health - Southeast Asia
Verified
Journal Article
Open access
SMSira Jam Munira
Sira Jam Munira
SNShiva R. Naga
Shiva R. Naga
IDIrum Fatima Dehraj
Irum Fatima Dehraj
KDKate Doyle
Kate Doyle
NKNaito Kanon
Naito Kanon
SSSenjuti Saha
Senjuti Saha
The Surveillance for Enteric Fever in Asia Project (SEAP) conducted blood culture surveillance for Salmonella enterica serotype Typhi (S. Typhi) and Paratyphi (S. Paratyphi) to provide an evidence base for prevention and control measures in Bangladesh, Nepal, and Pakistan. From October 2020 to September 2022, we conducted prospective clinical surveillance and retrospective laboratory surveillance at health facilities in Dhaka, Bangladesh; Kathmandu and Kavrepalanchok, Nepal; and Karachi, Pakistan. Patients were eligible if they were outpatients with three or more days of fever in the last week. In Nepal and Pakistan, inpatients were eligible if they had suspected or confirmed enteric fever; in Bangladesh, only inpatients with confirmed enteric fever were enrolled. Patients with blood culture-confirmed enteric fever identified by hospital laboratories and laboratory network sites were also enrolled. Patients completed interviews and medical records were reviewed and abstracted. All enrolled patients had blood cultures performed. Antibiograms were performed to characterize drug sensitivity. We summarized the data descriptively. A total of 17,593 patients were enrolled from 19 facilities. Of these, 8410 patients had culture-confirmed enteric fever. Case counts in all countries decreased in the early stages of the COVID-19 pandemic, but increased over time in Bangladesh and Pakistan. Case counts remained low throughout the study period in Nepal. In all countries, typhoid was more common than paratyphoid; the proportion of paratyphoid cases ranged from 8.4% in Pakistan to 16% in Nepal. Extensively drug-resistant typhoid was common in Pakistan (69%), but was not detected in Bangladesh or Nepal. Cases of enteric fever decreased during the COVID-19 pandemic, though it is not clear how much of this decrease relates to true changes in transmission versus health-seeking behavior. This project was funded by the Gates Foundation through INV-008335.

6 June 2025 in medRxiv
Verified
Preprint
Open access
PDF file
KLKristina W. Lai
Kristina W. Lai
COChris Orwa
Chris Orwa
JSJessica C. Seidman
Jessica C. Seidman
DGDenise O. Garrett
Denise O. Garrett
SSSamir K. Saha
Samir K. Saha
DMDouglas Ezra Morrison
Douglas Ezra Morrison
Motivation: Seroincidence—the rate of new infections in a population—is a key measure for understanding pathogen transmission dynamics and informing public health action. Estimating seroincidence from cross-sectional data is complicated by antibody waning, cross-reactivity, and individual heterogeneity in antibody responses. Implementation: serocalculator is an open-source R package that uses a likelihood-based framework incorporating antibody decay models, biological variability, and measurement noise to estimate seroincidence rates from cross-sectional serological data. General features: The package supports overall and stratified seroincidence estimation using single or multiple biomarkers. It requires three inputs: (1) a pre-estimated seroresponse model characterizing post-infection antibody waning; (2) noise parameters capturing biological and assay-related variability; and (3) quantitative antibody responses from a cross-sectional survey. It is computationally efficient, well-documented, and includes a point-and-click R Shiny interface. These features promote usability across research and public health. Availability: The package serocalculator is freely available on CRAN , with development versions on GitHub .

5 July 2025 in BMJ Public Health
Verified
Journal Article
Open access
PDF file
JVJuliana Barros Verruck
Juliana Barros Verruck
MPMarco Antonio Moreira Puga
Marco Antonio Moreira Puga
RORoberto Dias de Oliveira
Roberto Dias de Oliveira
PSPatricia Vieira da Silva
Patricia Vieira da Silva
VCVivek Charu
Vivek Charu
JCJulio Croda
Julio Croda
Objectives: To compare antispike IgG levels over a period of 182 days of follow-up in healthy adults who received full or fractional booster doses of BNT162b2 or AZD1222 after completing a primary series of Sinovac, BNT162b2 or AZD1222. Design: Double-blind, parallel-arm, phase IV randomised trial. Setting: The study was conducted in Campo Grande, Brazil, and participants were recruited in neighbourhoods with the lowest booster vaccine coverage. Follow-up visits were home based. Participants: 1451 (18–60 years) healthy adults who had received a full primary series of Sinovac (n=549), BNT162b2 (n=451) or AZD1222 (n=451) were included. Interventions: Participants were randomised to receive booster doses of either full or fractional doses of BNT162b2, AZD1222 or a full dose of Sinovac in the Sinovac-primed group. Antispike IgG antibody levels were measured at 0, 28, 84 and 182 days post-booster. Main outcome measures: Antispike IgG antibody levels were measured through blood samples at baseline and follow-up visits that were conducted 28, 84 and 182 days post-booster vaccination. Results: Throughout the 182-day follow-up period, full doses of BNT162b2 generated the highest antibody titres compared with fractional doses and other vaccines in all primary groups. Full-dose AZD1222 compared with its fractional dose showed a substantial difference only at day 28. BNT162b2 fractional doses produced higher antibodies than AZD1222 full doses. Sinovac-primed participants had the lowest baseline antibody titres, with Sinovac boosters continuing to show low titres, compared with BNT162b2 or AZD1222 full or fractional doses. Conclusions: Full doses of BNT162b2 consistently elicited higher antibody titres than fractional doses, AZD1222 and Sinovac at all time points. AZD1222 and Sinovac full doses produced lower titres than BNT162b2 fractional doses. Recommendations for using fractional doses of BNT162b2 as an alternative to full doses should be made cautiously, and further studies are needed to determine clinical protection levels. Trial registration number: NCT05343871 .